Monty Heinen, MD
Obstetrics & Gynecology · Eunice, LANPI 1538263728
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (48.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 61.6% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2021 at $8,322 and has fallen 92.3% since, to $639 in 2025. Among obstetrics & gynecology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 187 payments — averaging $67.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$8K
- Medical Device Business Services, Inc.$1K
- Applied Medical Resources Corporation$540
- Astellas Pharma US Inc$478
- AbbVie$426
- Pfizer$417
- plus $2K from 28 others
Across 83 payments — averaging $2430.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$150K
- Bayer$52K
What the payments were for
- Travel & lodging$3,23425%
- Food & beverage$3,28626%
- Education$6,18649%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 15 | $7,823 |
| Medical Device Business Services, Inc. | 4 | $1,088 |
| Applied Medical Resources Corporation | 2 | $540 |
| Astellas Pharma US Inc | 17 | $478 |
| AbbVie(2 entities) | 25 | $426 |
| Pfizer | 23 | $417 |
| Evofem Biosciences, Inc. | 21 | $408 |
| Exeltis, USA Inc. | 12 | $189 |
| AMAG Pharmaceuticals, Inc. | 2 | $132 |
| Therapeuticsmd, Inc. | 7 | $119 |
| Mayne Pharma Commercial LLC | 5 | $117 |
| Amgen | 7 | $113 |
| Millicent US Inc | 6 | $97 |
| Hologic Sales And Service, LLC | 5 | $96 |
| Sumitomo Pharma America, Inc. | 4 | $84 |
| Coopersurgical, Inc. | 3 | $80 |
| Mylan Pharmaceuticals Inc. | 4 | $67 |
| Ascend Therapeutics US, LLC | 4 | $51 |
| Merck | 3 | $41 |
| Johnson & Johnson | 2 | $41 |
| Lupin Inc. | 2 | $40 |
| Shield Therapeutics Inc | 2 | $40 |
| Dexcom, Inc. | 1 | $28 |
| Sage Therapeutics, LLC | 1 | $23 |
| Organon | 1 | $20 |
| Roche Diagnostics Corporation | 1 | $19 |
| Solventum Corporation | 1 | $19 |
| Meditrina | 1 | $18 |
| Gynesonics, Inc. | 1 | $18 |
| Avion Pharmaceuticals | 1 | $17 |
| Agile Therapeutics, Inc. | 1 | $16 |
| Zyla Life Sciences, Inc. | 1 | $16 |
| Gilead | 1 | $13 |
| Minerva Surgical, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$7,647
- GELPOINT$517
- GELPORT$517
- ALEXIS CONTAINED EXTRACTION SYSTEM$517
- INTRAROSA$115
How this compares
$12,706 in reported general payments places this provider in the 95th percentile of 608 obstetrics & gynecology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PremarinEstrogens, Conjugated | 91 | $30,320 |
| OzempicSemaglutide | 12 | $11,929 |
| MyrbetriqMirabegron | 23 | $10,491 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 41 | $7,227 |
| VeozahFezolinetant | 12 | $6,839 |
| Estradiol | 174 | $4,325 |
| PremproEstrogen,con/M-Progest Acet | 15 | $3,649 |
| Terconazole | 61 | $1,660 |
| ValacyclovirValacyclovir Hcl | 30 | $1,031 |
| Risedronate Sodium | 21 | $627 |
| Alendronate Sodium | 116 | $572 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 47 | $502 |
| ProgesteroneProgesterone, Micronized | 56 | $474 |
| Medroxyprogesterone Acetate | 40 | $372 |
| Norgestimate-Ethinyl Estradiol | 12 | $239 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPremarin, Prempro | $417 | $33,969106 claims |
| Astellas Pharma US IncMyrbetriq, Veozah | $478 | $17,33035 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 608 obstetrics & gynecology providers in Louisiana.
Other obstetrics & gynecology in Eunice
- Veronica GillispieNew Orleans$117K
- Rachel Bezdekla Place$105K
- Earl PeeperNew Orleans$95K
- Thomas PayneBaton Rouge$84K
- Catherine VanderloosShreveport$55K
- George MorrisNew Orleans$34K
- Russell PhelpsLafayette$31K
- Rachelle MeauxLafayette$31K
- Leonard BlantonBossier City$28K
- Janifer TropezNew Orleans$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.